BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-19: Form 8-K; Period of report 2015-11-13; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-11-12: Form 8-K; Period of report 2015-11-10; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.01.
- 2015-11-04: Form 8-K; Period of report 2015-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-08-05: Form 8-K; Period of report 2015-08-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-19 | 8-K | 2015-11-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 13, 2015, the Board of Directors (the "Board") of Biolase, Inc., a Delaware corporation (the "Company"), upon recommendation by the Compensation Committee of the Board ("Compensation Committee"), approved and adopted the terms of the Biolase, Inc. Deferred Compensation Plan (the "Plan") effective as of December 31, 2015. | htm_52758.htm |
| 2015-11-12 | 8-K | 2015-11-10 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 1.02 The information set forth in Item 1.01 of this Current Report is incorporated into this Item 1.02 by this reference. 3.01 On November 10, 2015, the Company was notified by the Nasdaq Stock Market that it is not in compliance with the continued listing requirements for the Nasdaq Capital Market contained in Nasdaq Listing Rule 5550(a)(2) requiring the Company’s listed securities to have a minimum bid price of $1.00 per share for 30 consecutive trading days. 3.03 As a result of the Fourth Amendment described in Item 1.01 above, the outstanding Rights expired on November 10, 2015. 5.03 Upon the expiration of the Rights as described in Item 3.03 above, on the Company filed a certificate of elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware on November 12, 2015, which decreased the number of authorized shares of Series B Junior Participating Cumulative Preferred Stock to zero, and as a result, under the Delaware General Corporation Law, the Series B Junior Participating Cumulative Preferred Stock shall no longer be an authorized series of preferred stock of the Company. | d35588d8k.htm |
| 2015-11-04 | 8-K | 2015-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2015, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2015. | htm_52657.htm |
| 2015-08-05 | 8-K | 2015-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2015, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2015. | htm_52257.htm |
| 2015-07-15 | 8-K | 2015-07-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 12, 2015, Jeffrey M. Nugent resigned as President and Chief Executive Officer of Biolase, Inc. (the "Company"), and resigned as a member of the Board of Directors (the "Board") of the Company. | htm_52145.htm |
| 2015-06-05 | 8-K | 2015-06-05 | 7.01 Regulation FD Disclosure | htm_51960.htm | |
| 2015-06-02 | 8-K | 2015-06-01 | 7.01 Regulation FD Disclosure | 7.01 On June 1, 2015, Jeffrey M. Nugent, President and Chief Executive Officer of Biolase, Inc. (the “Company”), and David C. Dreyer, Senior Vice President and Chief Financial Officer of the Company, delivered a presentation at the LD Micro Invitational conference in Los Angeles, California that included a written communication comprised of slides. | d936105d8k.htm |
| 2015-05-18 | 8-K | 2015-05-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On May 14, 2015, Biolase, Inc. (the "Company") entered into an employment agreement with Harold C. Flynn, Jr. to serve as President and Chief Executive Officer of Biolase, effective July 13, 2015. | htm_51851.htm |
| 2015-04-30 | 8-K | 2015-04-30 | 2.02 Results of Operations and Financial Condition | 2.02 On April 30, 2015, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2015. | htm_51737.htm |
| 2015-04-29 | 8-K | 2015-04-27 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On April 27, 2015, the 2015 Annual Meeting of Stockholders of Biolase, Inc. (the "Company") was held at the Company's headquarters, 4 Cromwell, Irvine, California. | htm_51717.htm |
| 2015-03-06 | 8-K | 2015-03-06 | 8.01 Other Events | 8.01 On March 6, 2015, Biolase, Inc. (the "Company") issued a press release announcing the date of the Company’s 2015 Annual Meeting of Stockholders and the record date for such meeting, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. | htm_51411.htm |
| 2015-03-04 | 8-K | 2015-03-04 | 2.02 Results of Operations and Financial Condition | 2.02 On March 4, 2015, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2014. | htm_51400.htm |
| 2015-03-02 | 8-K | 2015-02-24 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On February 24, 2015, Biolase, Inc. ("Biolase") entered into an employment agreement with David Dreyer to serve as Senior Vice President and Chief Financial Officer of Biolase, effective March 9, 2015. | htm_51380.htm |
| 2015-02-05 | 8-K/A | 2015-01-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 5, 2015, Biolase, Inc. (the "Company") reported on a Current Report on Form 8-K (the "February 5, 2015 Form 8-K") that, effective January 31, 2015, Frederick D. Furry resigned from his position with the Company. | htm_51257.htm |
| 2015-02-05 | 8-K | 2015-01-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of January 31, 2015, Frederick D. Furry resigned from his position as Chief Financial Officer of Biolase, Inc. (the "Company"). | htm_51249.htm |